Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease

Brain

Volumn 134, Issue 3, 2011, Pages 845-855

  Melzer, Tracy R ^a,b   Watts, Richard ^a,c   MacAskill, Michael R ^a,b   Pearson, John F ^b   Rüeger, Sina ^a,d   Pitcher, Toni L ^a,b   Livingston, Leslie ^a,b   Graham, Charlotte ^a,b   Keenan, Ross ^e   Shankaranarayanan, Ajit ^f   Alsop, David C ^g,h   Dalrymple Alford, John C ^a,b,c   Anderson, Tim J ^a,b,i  

^a Van der Veer Institute New Zealand   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

^d ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^e Christchurch Radiology Group   (New Zealand)

^f GE HEALTHCARE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

arterial spin labelling; cognition; magnetic resonance imaging; network analysis; Parkinson's disease; perfusion

Indexed keywords

ADULT; AGED; ANTERIOR CINGULATE; ARTERIAL SPIN LABELING; ARTICLE; BRAIN PERFUSION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CUNEUS; DEMENTIA; DISEASE COURSE; FEMALE; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE FRONTAL GYRUS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; PARIETO-OCCIPITAL SULCUS; PARKINSON DISEASE; POSTCENTRAL GYRUS; PRECUNEUS; PRIMARY MOTOR CORTEX; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PUTAMEN; SPIN LABELING;

ADULT; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79952141381     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq377     Document Type: Article

References (52)

1. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-9.
2. Alexander GE, Moeller JR. Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders: a principal component approach to modeling brain function in disease. Hum Brain Mapp 1994;2:79-94. (Pubitemid 124000443)
3. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93-100. (Pubitemid 30033655)
4. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-51. (Pubitemid 40825026)
5. Asllani I, Habeck C, Scarmeas N, Borogovac A, Brown TR, Stern Y. Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab 2007;28:725-36.
6. 18F]FDG-PET. Mov Disord 2001;16:1014-22. (Pubitemid 36041213)
7. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 2010;214:303-17.
8. Borghammer P, Cumming P, Aanerud J, Förster S, Gjedde A. Subcortical elevation of metabolism in Parkinson's disease - a critical reappraisal in the context of global mean normalization. Neuroimage 2009a; 47:1514-21.
9. Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage 2009b; 45:249-57.
10. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, et al. Normalization in PET group comparison studies-The importance of a valid reference region. Neuroimage 2008;40:529-40.
11. Buijs PC, Krabbe-Hartkamp MJ, Bakker CJ, de Lange EE, Ramos LM, Breteler MM, et al. Effect of age on cerebral blood flow: measurement with ungated two-dimensional phase-contrast MR angiography in 250 adults. Radiology 1998;209:667-74. (Pubitemid 28564897)
12. Caviness JN, Driverdementiaunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-7. (Pubitemid 47325034)
13. Dai W, Garcia D, de Bazelaire C, Alsop DC. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 2008;60:1488-97.
14. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson's disease. Neurology 2010;75:1717-25.
15. Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med 1992;23:37-45.
16. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-24. (Pubitemid 351155975)
17. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-32. (Pubitemid 47405003)
18. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
19. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-57.
20. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153-63.
21. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003;20:1309-19. (Pubitemid 37268148)
22. Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction. New York: Springer; 2009.
23. Hershey T, Black KJ, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:844-51. (Pubitemid 36782981)
24. Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008;28:4201-9.
25. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009;24:854-62.
26. Hsu J-L, Jung T-P, Hsu C-Y, Hsu W-C, Chen Y-K, Duann J-R, et al. Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction. Eur J Nucl Med Mol Imaging 2007;34:1458-66. (Pubitemid 47312576)
27. 18FDG-PET study. Brain 2000;123:340-52. (Pubitemid 30055157)
28. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
29. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007a; 34:714-23. (Pubitemid 44827754)
30. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007b; 130:1834-46. (Pubitemid 47343798)
31. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749-57.
32. Kasama S, Tachibana H, Kawabata K, Yoshikawa H. Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging. Dement Geriatr Cogn Disord 2005;19:266-75. (Pubitemid 40663320)
33. Kobari M, Fukuuchi Y, Shinohara T, Obara K, Nogawa S. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders. J Neurol Sci 1995;128:212-8.
34. Lemaître H, Crivello F, Grassiot B, Alpérovitch A, Tzourio C, Mazoyer B. Age-and sex-related effects on the neuroanatomy of healthy elderly. Neuroimage 2005;26:900-11. (Pubitemid 40825032)
35. Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration. Mov Disord 2009;24:1504-11.
36. Ma Y, Huang C, Dyke JP, Pan H, Alsop D, Feigin A, et al. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010;30:505-9.
37. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
38. Melamed E, Globus M, Mildworf B. Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations. J Neurol Neurosurg Psychiatry 1986;49:1301-4. (Pubitemid 17174034)
39. Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002;159:746.
40. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005;107:396-403. (Pubitemid 40980384)
41. Moeller JR, Habeck CG. Reciprocal benefits of mass-univariate and multivariate modeling in brain mapping: applications to event-related functional MRI, H2150-, and FDG-PET. Int J Biomed Imaging 2006;2006:1-13.
42. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 1997;9:87-94. (Pubitemid 28045345)
43. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 2005;53:695-9. (Pubitemid 41623495)
44. Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B, et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009;24:414-21.
45. Osaki Y, Morita Y, Fukumoto M, Akagi N, Yoshida S, Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord 2005;20:999-1005. (Pubitemid 41419517)
46. Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 2009;35:141-7.
47. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60. (Pubitemid 23060253)
48. Scarmeas N, Habeck CG, Zarahn E, Anderson KE, Park A, Hilton J, et al. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage 2004;23:35-45. (Pubitemid 39119433)
49. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 2009;45:1241-52.
50. Turk M, Pentland A. Eigenfaces for recognition. J Cogn Neurosci 1991;3:71-86.
51. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997;38:797-802. (Pubitemid 27204060)
52. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, Middelkoop HAM. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1182-7. (Pubitemid 350057278)